Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mizoribine vs mycophenolic acid as initial immunosuppression in deceased donor kidney transplantation
ChiCTR2500107201Phase 4Not yet recruiting
- Sponsor
- Guangxi Medical University Second Affiliated Hospital
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of mizoribine in kidney allograft rejection (2 arms), sponsored by Guangxi Medical University Second Affiliated Hospital. Primary endpoint: acute rejection at 24 months. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
mizoribine
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on ChiCTR2500107201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107201.